Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alaunos Therapeutics, Inc.ZIOP · Entity 8339 | Director | March 04, 2021 | May 06, 2021 |
| Amneal Pharmaceuticals, Inc.AMRX · Entity 820 | Director | September 17, 2026 | September 21, 2026 |
| Ampio Pharmaceuticals, Inc.AMPE · Entity 112383 | Director | June 09, 2023 | June 13, 2023 |
| BIOSPECIFICS TECHNOLOGIES CORPBSTC · Entity 144844 | Director · Chief Executive Officer | October 23, 2019 | October 25, 2019 |
| Benitec Biopharma Inc.BNTC · Entity 5596 | Director | June 29, 2026 | June 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alaunos Therapeutics, Inc.
Report date March 04, 2021 · Filed May 06, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,167 |
Reported balance
After 2021-03-04 transaction · row 1
1 source rowRow 1 · 2021-03-04 · Grant · Acquired 4,167 · Balance 4,167 F1: The shares will vest on 5/19/2021. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.31 · Expires 2031-03-03 | Direct | 31,250 |
Reported balance
After 2021-03-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-03-04 · Grant · Acquired 31,250 · Balance 31,250 F2: 1/3rd of the shares underlying this option will vest on 4/4/2021, 5/4/2021 and 5/19/2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares will vest on 5/19/2021.
F2: 1/3rd of the shares underlying this option will vest on 4/4/2021, 5/4/2021 and 5/19/2021.
Amneal Pharmaceuticals, Inc.
Report date September 17, 2026 · Filed September 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 75,077 |
Reported balance
After 2026-09-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-17 · Gift · Disposed 20,445 · Balance 75,077 F1: On September 17th, the reporting person transferred 20,445 shares of Class A Common Stock to a trust for no consideration. The Reporting person is trustee of the trust. |
| Class A Common StockSEC Table I · non-derivative | IndirectBy Trust | 113,944 |
Reported balance
Holding disclosure · report date 2026-09-17 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 113,944 F1: On September 17th, the reporting person transferred 20,445 shares of Class A Common Stock to a trust for no consideration. The Reporting person is trustee of the trust. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 17th, the reporting person transferred 20,445 shares of Class A Common Stock to a trust for no consideration. The Reporting person is trustee of the trust.
Ampio Pharmaceuticals, Inc.
Report date June 09, 2023 · Filed June 13, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 146,858 |
Reported balance
After 2023-06-09 transaction · row 1
1 source rowRow 1 · 2023-06-09 · Purchase · Acquired 21,858 · Balance 146,858 F1: The price reported is a weighted average. Shares were purchased in multiple transactions at prices ranging from $0.2751 to $0.30, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is a weighted average. Shares were purchased in multiple transactions at prices ranging from $0.2751 to $0.30, inclusive.
BIOSPECIFICS TECHNOLOGIES CORP
Report date October 23, 2019 · Filed October 25, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.52 · Expires 2029-10-23 | Direct | 85,000 |
Reported balance
After 2019-10-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-10-23 · Grant · Acquired 85,000 · Balance 85,000 F1: The stock options were granted under the BioSpecifics Technologies Corp. 2019 Omnibus Incentive Compensation Plan. F2: The stock options vest ratably over the four-year period following the date of grant, October 23, 2019, subject to the Reporting Person's continued service to the employer through the vesting date. In the event the Reporting Person is terminated (a) by the employer without cause, (b) by the Reporting Person for good reason, or (c) by the employer without cause or by the Reporting Person for good reason, in each case upon or within one (1) year following a change of control, the stock options will fully vest. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options were granted under the BioSpecifics Technologies Corp. 2019 Omnibus Incentive Compensation Plan.
F2: The stock options vest ratably over the four-year period following the date of grant, October 23, 2019, subject to the Reporting Person's continued service to the employer through the vesting date. In the event the Reporting Person is terminated (a) by the employer without cause, (b) by the Reporting Person for good reason, or (c) by the employer without cause or by the Reporting Person for good reason, in each case upon or within one (1) year following a change of control, the stock options will fully vest.
Benitec Biopharma Inc.
Report date June 29, 2026 · Filed June 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,097 |
Reported balance
After 2026-06-29 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-29 · Gift · Disposed 51,813 · Balance 52,097 F1: The reporting person transferred 51,813 shares of Benitec Biopharma Inc. common stock to a donor-advised fund sponsored by a charitable organization under Section 501(c)(3) of the Internal Revenue Code. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person transferred 51,813 shares of Benitec Biopharma Inc. common stock to a donor-advised fund sponsored by a charitable organization under Section 501(c)(3) of the Internal Revenue Code.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Dicerna Pharmaceuticals Inc
Report date December 28, 2021 · Filed December 29, 2021
Section 16 reporting ended · disclosed 2021-12-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-12-28 transaction · row 1
1 source rowRow 1 · 2021-12-28 · Other · Disposed 4,666 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of December 28, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $38.25 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-12-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-12-28 · Disposition to issuer · Disposed 3,333 · Balance 0 F2: Each restricted stock unit ("RSU") represents the contingent right to receive one Share. F3: At the Effective Time, each Issuer RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting). |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.13 | Direct | 0 |
Reported balance
After 2021-12-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-12-28 · Disposition to issuer · Disposed 8,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.76 | Direct | 0 |
Reported balance
After 2021-12-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-12-28 · Disposition to issuer · Disposed 25,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.44 | Direct | 0 |
Reported balance
After 2021-12-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-12-28 · Disposition to issuer · Disposed 33,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.61 | Direct | 0 |
Reported balance
After 2021-12-28 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-12-28 · Disposition to issuer · Disposed 21,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.47 | Direct | 0 |
Reported balance
After 2021-12-28 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-12-28 · Disposition to issuer · Disposed 15,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of December 28, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $38.25 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.
F2: Each restricted stock unit ("RSU") represents the contingent right to receive one Share.
F3: At the Effective Time, each Issuer RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting).
F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting).
Impax Laboratories, LLC
Report date May 04, 2018 · Filed May 08, 2018
Section 16 reporting ended · disclosed 2018-05-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 1
1 source rowRow 1 · 2018-05-04 · Disposition to issuer · Disposed 8,020 · Balance 0 F1: Common Stock disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017 (the "BCA"), by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017, according to which each share of Common Stock held by the reporting person was converted into the right to receive one share of Class A common stock of Holdco ("Class A Common Stock"). |
| Restricted Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 2
1 source rowRow 2 · 2018-05-04 · Disposition to issuer · Disposed 3,281 · Balance 0 F2: Shares of restricted common stock disposed of pursuant to the terms of the BCA, according to which each share of restricted stock held by the reporting person fully vested and was exchanged for one share of Class A Common Stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.40 · Expires 2027-05-16 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-05-04 · Disposition to issuer · Disposed 7,931 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.45 · Expires 2026-11-23 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-05-04 · Disposition to issuer · Disposed 20,445 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Common Stock disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017 (the "BCA"), by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017, according to which each share of Common Stock held by the reporting person was converted into the right to receive one share of Class A common stock of Holdco ("Class A Common Stock").
F2: Shares of restricted common stock disposed of pursuant to the terms of the BCA, according to which each share of restricted stock held by the reporting person fully vested and was exchanged for one share of Class A Common Stock.
F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 06, 2021 Filed May 7, 2021 18:06 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 46,218 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-030806 · doc4.xml · derivative · entry 3 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 46,218 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: On May 5, 2020 the reporting person was granted 46,218 restricted stock units vesting on May 6, 2021. F3 · derivative.expiration_date: On May 5, 2020 the reporting person was granted 46,218 restricted stock units vesting on May 6, 2021. Read SEC document |
| May 06, 2021 Filed May 7, 2021 18:06 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 46,218 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-030806 · doc4.xml · nonDerivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,085 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| May 05, 2021 Filed May 7, 2021 18:06 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 35,406 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-030806 · doc4.xml · derivative · entry 2 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,406 Underlying: Class A Common Stock · 35,406 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. F2 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document |
| March 04, 2021 Filed May 6, 2021 23:21 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantStock Option (right to buy) · Derivative | 31,250 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-21-030738 · doc4.xml · derivative · entry 2 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,250 Underlying: Common Stock · 31,250 shares Expires 2031-03-03 F2 · derivative.exercise_date: 1/3rd of the shares underlying this option will vest on 4/4/2021, 5/4/2021 and 5/19/2021. Read SEC document |
| March 04, 2021 Filed May 6, 2021 23:21 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantCommon Stock | 4,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-030738 · doc4.xml · nonDerivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,167 F1 · shares: The shares will vest on 5/19/2021. Read SEC document |
| December 09, 2020 Filed Dec 11, 2020 21:59 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | GrantOptions (right to buy) · Derivative | 23,601 | $0.00 Strike: $2.98 | $0.00 |
DisclosureSEC source: 0001062993-20-006261 · form4.xml · derivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,601 Underlying: Common Stock · 23,601 shares Expires 2030-12-09 F1 · derivative.exercise_date: The stock options will vest in three substantially equal installments on the day prior to each of the Issuer???s next three annual stockholder meetings occurring immediately following the date of grant. Read SEC document |
| October 08, 2020 Filed Oct 13, 2020 20:55 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantStock Option (right to buy) · Derivative | 146,190 | $0.00 Strike: $2.76 | $0.00 |
DisclosureSEC source: 0001209191-20-054667 · doc4.xml · derivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,190 Underlying: Common Stock · 146,190 shares Expires 2030-10-08 F1 · derivative.exercise_date: The shares underlying this option will vest on September 21, 2022, subject to the Reporting Person's continuous service to the Issuer through such date; vesting of all shares subject to the option shall vest upon a change of control. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 00:03 UTC | Dicerna Pharmaceuticals Inc DRNA · Entity 131951 | GrantDirector Stock Option (Right to Buy) · Derivative | 21,000 | $0.00 Strike: $21.61 | $0.00 |
DisclosureSEC source: 0000899243-20-016731 · doc4.xml · derivative · entry 2 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2030-06-14 F2 · derivative.exercise_date: This option vests monthly over 12 months from the Grant Date in substantially equal monthly installments, provided that the option vests in full on the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date or, if earlier, such annual meeting. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 00:03 UTC | Dicerna Pharmaceuticals Inc DRNA · Entity 131951 | GrantRestricted Stock Units · Derivative | 4,666 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-016731 · doc4.xml · derivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,666 Underlying: Common Stock · 4,666 shares Expires not disclosed F1 · derivative.exercise_price: Represents restricted stock units ("RSUs") that vest 12 months from June 15, 2020 ("Grant Date"), provided that these RSUs vest in full on the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer through such vesting date or, if earlier, such annual meeting. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. F1 · derivative.exercise_date: Represents restricted stock units ("RSUs") that vest 12 months from June 15, 2020 ("Grant Date"), provided that these RSUs vest in full on the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer through such vesting date or, if earlier, such annual meeting. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. F1 · derivative.expiration_date: Represents restricted stock units ("RSUs") that vest 12 months from June 15, 2020 ("Grant Date"), provided that these RSUs vest in full on the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer through such vesting date or, if earlier, such annual meeting. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| May 07, 2020 Filed May 7, 2020 21:23 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 6,459 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-012257 · doc4.xml · derivative · entry 3 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 6,459 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: On May 6, 2019, the reporting person was granted 6,459 restricted stock units vesting on May 7, 2020. F3 · derivative.expiration_date: On May 6, 2019, the reporting person was granted 6,459 restricted stock units vesting on May 7, 2020. Read SEC document |
| May 07, 2020 Filed May 7, 2020 21:23 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 6,459 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012257 · doc4.xml · nonDerivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,867 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| May 05, 2020 Filed May 7, 2020 21:23 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 46,218 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-012257 · doc4.xml · derivative · entry 2 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,218 Underlying: Class A Common Stock · 46,218 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. F2 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document |
| October 23, 2019 Filed Oct 25, 2019 16:47 UTC | BIOSPECIFICS TECHNOLOGIES CORP BSTC · Entity 144844 | GrantStock Option (Right to Buy) · Derivative | 85,000 | $0.00 Strike: $46.52 | $0.00 |
DisclosureSEC source: 0001062993-19-004037 · form4.xml · derivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2029-10-23 F1 · kind: The stock options were granted under the BioSpecifics Technologies Corp. 2019 Omnibus Incentive Compensation Plan. F2 · derivative.exercise_date: The stock options vest ratably over the four-year period following the date of grant, October 23, 2019, subject to the Reporting Person's continued service to the employer through the vesting date. In the event the Reporting Person is terminated (a) by the employer without cause, (b) by the Reporting Person for good reason, or (c) by the employer without cause or by the Reporting Person for good reason, in each case upon or within one (1) year following a change of control, the stock options will fully vest. Read SEC document |
| June 20, 2019 Filed Jun 22, 2019 00:00 UTC | Dicerna Pharmaceuticals Inc DRNA · Entity 131951 | GrantDirector Stock Option (right to buy) · Derivative | 33,000 | $0.00 Strike: $15.44 | $0.00 |
DisclosureSEC source: 0000899243-19-017860 · doc4.xml · derivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2029-06-20 F1 · derivative.exercise_date: This option vests monthly over 12 months from June 20, 2019 ("Grant Date") in substantially equal monthly installments, provided that the option will vest in full on the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer through each such date or, if earlier, such annual meeting. Read SEC document |
| May 08, 2019 Filed May 8, 2019 21:50 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 6,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001723128-19-000074 · wf-form4_155735219336381.xml · derivative · entry 4 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 6,107 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On May 7, 2018, the reporting person was granted 6,107 restricted stock units vesting on May 8, 2019. F4 · derivative.expiration_date: On May 7, 2018, the reporting person was granted 6,107 restricted stock units vesting on May 8, 2019. Read SEC document |
| May 08, 2019 Filed May 8, 2019 21:50 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 6,107 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001723128-19-000074 · wf-form4_155735219336381.xml · nonDerivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,408 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| May 06, 2019 Filed May 8, 2019 21:50 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 6,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001723128-19-000074 · wf-form4_155735219336381.xml · derivative · entry 3 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,459 Underlying: Class A Common Stock · 6,459 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Restricted stock units have no expiration date. F3 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Restricted stock units have no expiration date. Read SEC document |
| May 06, 2019 Filed May 8, 2019 21:50 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 28,044 | $0.00 Strike: $14.05 | $0.00 |
DisclosureSEC source: 0001723128-19-000074 · wf-form4_155735219336381.xml · derivative · entry 2 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,044 Underlying: Class A Common Stock · 28,044 shares Expires 2029-05-06 F2 · derivative.exercise_date: The option vests on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document |
| March 28, 2019 Filed Mar 30, 2019 00:00 UTC | Dicerna Pharmaceuticals Inc DRNA · Entity 131951 | GrantDirector Stock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $14.13 | $0.00 |
DisclosureSEC source: 0000899243-19-009327 · doc4.xml · derivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2029-03-28 F1 · derivative.exercise_date: This option vests as to one-third of the underlying shares on the one year anniversary of the date of grant and as to the remaining two-thirds of the shares in quarterly installments over the two-year period thereafter, subject in each case to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| August 13, 2018 Filed Aug 16, 2018 01:02 UTC | Dicerna Pharmaceuticals Inc DRNA · Entity 131951 | GrantDirector Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $14.76 | $0.00 |
DisclosureSEC source: 0000905148-18-000717 · form4.xml · derivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-08-13 F1 · derivative.exercise_date: This option vests as to one-third of the underlying shares on the one year anniversary of the date of grant and as to the remaining two-thirds of the shares in quarterly installments over the two-year period thereafter, subject in each case to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| May 07, 2018 Filed May 8, 2018 23:26 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 6,107 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-011948 · doc4.xml · derivative · entry 5 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,107 Underlying: Class A Common Stock · 6,107 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F6 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on May 07, 2019 and have no expiration date. F6 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on May 07, 2019 and have no expiration date. Read SEC document |
| May 07, 2018 Filed May 8, 2018 23:26 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 24,977 | $0.00 Strike: $15.01 | $0.00 |
DisclosureSEC source: 0000899243-18-011948 · doc4.xml · derivative · entry 4 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,977 Underlying: Class A Common Stock · 24,977 shares Expires 2028-05-07 F4 · derivative.exercise_date: The option vests in four equal annual installments beginning on May 07, 2019. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:23 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,445 | Not disclosed Strike: $14.45 | Not disclosed |
DisclosureSEC source: 0001003642-18-000085 · wf-form4_152581093204247.xml · derivative · entry 4 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,445 shares Expires 2026-11-23 F3 · shares: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · price: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · derivative.exercise_date: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:23 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,931 | Not disclosed Strike: $16.40 | Not disclosed |
DisclosureSEC source: 0001003642-18-000085 · wf-form4_152581093204247.xml · derivative · entry 3 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,931 shares Expires 2027-05-16 F3 · shares: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · price: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · derivative.exercise_date: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:23 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerRestricted Common Stock | 3,281 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001003642-18-000085 · wf-form4_152581093204247.xml · nonDerivative · entry 2 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · shares: Shares of restricted common stock disposed of pursuant to the terms of the BCA, according to which each share of restricted stock held by the reporting person fully vested and was exchanged for one share of Class A Common Stock. F2 · price: Shares of restricted common stock disposed of pursuant to the terms of the BCA, according to which each share of restricted stock held by the reporting person fully vested and was exchanged for one share of Class A Common Stock. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:23 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerCommon Stock | 8,020 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001003642-18-000085 · wf-form4_152581093204247.xml · nonDerivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Common Stock disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017 (the "BCA"), by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017, according to which each share of Common Stock held by the reporting person was converted into the right to receive one share of Class A common stock of Holdco ("Class A Common Stock"). F1 · price: Common Stock disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017 (the "BCA"), by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017, according to which each share of Common Stock held by the reporting person was converted into the right to receive one share of Class A common stock of Holdco ("Class A Common Stock"). Read SEC document |
| May 04, 2018 Filed May 8, 2018 23:26 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 20,445 | Not disclosed Strike: $14.45 | Not disclosed |
DisclosureSEC source: 0000899243-18-011948 · doc4.xml · derivative · entry 3 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,445 Underlying: Class A Common Stock · 20,445 shares Expires 2026-11-23 F3 · price: Received pursuant to the BCA in exchange for an option to purchase an equal number of shares of Impax common stock. F2 · derivative.exercise_date: The option is vested and currently exercisable. Read SEC document |
| May 04, 2018 Filed May 8, 2018 23:26 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 7,931 | Not disclosed Strike: $16.40 | Not disclosed |
DisclosureSEC source: 0000899243-18-011948 · doc4.xml · derivative · entry 2 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,931 Underlying: Class A Common Stock · 7,931 shares Expires 2027-05-16 F3 · price: Received pursuant to the BCA in exchange for an option to purchase an equal number of shares of Impax common stock. F2 · derivative.exercise_date: The option is vested and currently exercisable. Read SEC document |
| May 04, 2018 Filed May 8, 2018 23:26 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantClass A Common Stock | 11,301 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-011948 · doc4.xml · nonDerivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,301 F1 · price: Received in exchange for 11,301 shares of Impax Laboratories, Inc. ("Impax") common stock pursuant to the Business Combination Agreement, dated as of October 17, 2017, among Impax, Amneal Pharmaceuticals LLC, Atlas Holdings, Inc. and K2 Merger Sub Corporation (as amended, the "BCA"). Read SEC document |
| May 16, 2017 Filed May 17, 2017 15:50 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | GrantStock Option (Right-to-Buy) · Derivative | 7,931 | $0.00 Strike: $16.40 | $0.00 |
DisclosureSEC source: 0001003642-17-000055 · wf-form4_149505063540951.xml · derivative · entry 2 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,931 Underlying: Common Stock · 7,931 shares Expires 2027-05-16 F1 · derivative.exercise_date: The option fully vests on the earlier of (i) May 16, 2018, which is the first anniversary of the date of grant and (ii) one day before the date of the Company's next annual meeting of stockholders. Read SEC document |
| May 16, 2017 Filed May 17, 2017 15:50 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | GrantCommon Stock | 3,281 | $0.00 | $0.00 |
DisclosureSEC source: 0001003642-17-000055 · wf-form4_149505063540951.xml · nonDerivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,301 Read SEC document |
| November 23, 2016 Filed Nov 28, 2016 16:52 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | GrantStock Option (Right-to-Buy) · Derivative | 20,445 | $0.00 Strike: $14.45 | $0.00 |
DisclosureSEC source: 0001003642-16-000051 · wf-form4_148036991544071.xml · derivative · entry 2 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,445 Underlying: Common Stock · 20,445 shares Expires 2026-11-23 F1 · derivative.exercise_date: The option fully vests on the earlier of (i) November 23, 2017, which is the first anniversary of the date of grant and (ii) one day before the date of the Company's next annual meeting of stockholders. Read SEC document |
| November 23, 2016 Filed Nov 28, 2016 16:52 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | GrantCommon Stock | 8,020 | $0.00 | $0.00 |
DisclosureSEC source: 0001003642-16-000051 · wf-form4_148036991544071.xml · nonDerivative · entry 1 BUCHI J KEVIN · CIK 0001209726 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,020 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.